213 related articles for article (PubMed ID: 22645138)
1. Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.
Chen L; Liu C; Ko FC; Xu N; Ng IO; Yam JW; Zhu G
J Biol Chem; 2012 Jul; 287(31):26104-14. PubMed ID: 22645138
[TBL] [Abstract][Full Text] [Related]
2. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
3. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
4. START-GAP1/DLC1 is localized in focal adhesions through interaction with the PTB domain of tensin2.
Kawai K; Kitamura SY; Maehira K; Seike J; Yagisawa H
Adv Enzyme Regul; 2010; 50(1):202-15. PubMed ID: 19895840
[No Abstract] [Full Text] [Related]
5. Solution structure of tensin2 SH2 domain and its phosphotyrosine-independent interaction with DLC-1.
Dai K; Liao S; Zhang J; Zhang X; Tu X
PLoS One; 2011; 6(7):e21965. PubMed ID: 21765928
[TBL] [Abstract][Full Text] [Related]
6. Individual domains of Tensin2 exhibit distinct subcellular localisations and migratory effects.
Hafizi S; Sernstad E; Swinny JD; Gomez MF; Dahlbäck B
Int J Biochem Cell Biol; 2010 Jan; 42(1):52-61. PubMed ID: 19747564
[TBL] [Abstract][Full Text] [Related]
7. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
8. 1H, 15N and 13C chemical shift assignments of the SH2 domain of human tensin2 (TENC1).
Chen L; Liu C; Rui F; Zhu G
Biomol NMR Assign; 2011 Oct; 5(2):211-4. PubMed ID: 21461930
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
10. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
11. The protein-tyrosine kinase Syk interacts with the C-terminal region of tensin2.
Moon KD; Zhang X; Zhou Q; Geahlen RL
Biochim Biophys Acta; 2012 Feb; 1823(2):199-205. PubMed ID: 22019427
[TBL] [Abstract][Full Text] [Related]
12. CDK5 is a major regulator of the tumor suppressor DLC1.
Tripathi BK; Qian X; Mertins P; Wang D; Papageorge AG; Carr SA; Lowy DR
J Cell Biol; 2014 Dec; 207(5):627-42. PubMed ID: 25452387
[TBL] [Abstract][Full Text] [Related]
13. Interaction of DISC1 with the PTB domain of Tensin2.
Goudarzi S; Smith LJ; Schütz S; Hafizi S
Cell Mol Life Sci; 2013 May; 70(9):1663-72. PubMed ID: 23233134
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.
Cao X; Voss C; Zhao B; Kaneko T; Li SS
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1455-60. PubMed ID: 22307599
[TBL] [Abstract][Full Text] [Related]
15. Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration.
Chen H; Duncan IC; Bozorgchami H; Lo SH
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):733-8. PubMed ID: 11792844
[TBL] [Abstract][Full Text] [Related]
16. Tensin1 positively regulates RhoA activity through its interaction with DLC1.
Shih YP; Sun P; Wang A; Lo SH
Biochim Biophys Acta; 2015 Dec; 1853(12):3258-65. PubMed ID: 26427649
[TBL] [Abstract][Full Text] [Related]
17. START-GAP2/DLC2 is localized in focal adhesions via its N-terminal region.
Kawai K; Seike J; Iino T; Kiyota M; Iwamae Y; Nishitani H; Yagisawa H
Biochem Biophys Res Commun; 2009 Mar; 380(4):736-41. PubMed ID: 19250640
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
19. LD Motif Recognition by Talin: Structure of the Talin-DLC1 Complex.
Zacharchenko T; Qian X; Goult BT; Jethwa D; Almeida TB; Ballestrem C; Critchley DR; Lowy DR; Barsukov IL
Structure; 2016 Jul; 24(7):1130-41. PubMed ID: 27265849
[TBL] [Abstract][Full Text] [Related]
20. Characterization of DLC1-SAM equilibrium unfolding at the amino acid residue level.
Yang S; Noble CG; Yang D
Biochemistry; 2009 May; 48(19):4040-9. PubMed ID: 19317456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
